A framed reading of the Thymosin Beta-4 record. No exam room. No storefront.

Who we are

TB-500 Doctor is a reading bench for the Thymosin Beta-4 fragment. What the peer-reviewed record actually reports on TB-500 and its 43-amino-acid parent peptide gets pulled onto the bench, boxed inside a labeled frame, and sourced. That is the whole operation. No exam room sits behind this URL, no storefront, no dispensary — the site treats no patient, writes no prescription, and moves no product. What it does is read the literature and write down what each frame contains.

The 'doctor' in the domain is a stance toward the record, not a service on offer. It marks the posture of someone reading the studies closely — checking what a trial measured against what a later citation claimed — not a practitioner taking appointments. There are no consultations here and nothing changing hands. The method is curatorial: read the TB-500 record, frame what is in it, mark what is missing, and flag where the loudest claims drift from what the data measured.

What we publish, and how

Each page on this site is structured around a single editorial question — what TB-500 is, what it does in the research record, how it has been dosed in published studies, what the clinical trial program for the parent peptide has shown, and what the open questions still are.

Our sourcing is restricted to peer-reviewed primary literature (PubMed, PMC, peer-reviewed journals), registered clinical trials (ClinicalTrials.gov, EU CTR), and regulator-grade documentation (FDA labels, WADA Prohibited List). Vendor pages, supplement-industry whitepapers, and forum posts are not sources. Where vendor-circulated claims appear — the 'two- to three-hour half-life' figure for the 7-AA fragment, for example — we flag them as vendor-origin and note the absence of peer-reviewed support.

The Block Frame visual treatment is part of the editorial method. Every claim sits inside a labeled bordered block. Categories are color-coded: pink for molecular mechanism, sky blue for clinical trial results, lime for preclinical animal-model data, gold for regulatory and WADA status. The framing is the disclosure — readers can see at a glance which kind of evidence a given block represents.

What we do not do

No line on this site is medical advice, and none is a dose to copy. The bench endorses no supplier of TB-500 or any other peptide and vouches for none. There is no clinical team here, no pharmacist, no prescriber, no room you can walk into — only the record and the frames built around it.

Where our writing describes published research doses (the 5-microgram topical dose in the Sosne corneal alkali-burn study, the 150-microgram intraperitoneal regimen in the Smart epicardial study, the 1,260 mg IV dose in the Ruff Phase I trial), those numbers are reported as research-context only — they describe what investigators administered to rats, mice, pigs, or healthy adult volunteers under research protocols. They are not human therapeutic recommendations and they are not extrapolatable to underground or non-clinical use.

Regulatory context

TB-500 is not approved by the FDA, EMA, MHRA, TGA, PMDA, or any other major regulator for any human indication. The 43-AA parent peptide has reached Phase III in ophthalmic indications and Phase II in cardiac indications without yet receiving marketing authorization.

TB-500 is prohibited at all times under the World Anti-Doping Code, listed under sections S2 and S0 of the Prohibited List. Equine doping-control laboratories have validated LC-MS detection of TB-500 in plasma and urine after intravenous administration, and the analytical infrastructure to enforce the ban exists in human anti-doping practice.